Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

摘要

This randomized phase III trial compared FOLFIRI plus bevacizumab with mFOLFOX6 plus bevacizumab as the first-line treatment for patients with metastatic colorectal cancer. This direct comparative phase III trial demonstrated that FOLFIRI plus bevacizumab was non-inferior to mFOLFOX6 plus bevacizumab in terms of progression-free survival, and was associated with favorable quality of life profiles.FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with bevacizumab.